Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BHVN - Biohaven Ltd.
Market Cap 1.32B P/E - EPS this Y -55.80% Ern Qtrly Grth -
Income -746.6M Forward P/E -3.96 EPS next Y 27.70% 50D Avg Chg -13.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 3.40 EPS next 5Y - 52W High Chg -28.00%
Recommedations 1.50 Quick Ratio 2.85 Shares Outstanding 94.54M 52W Low Chg 248.00%
Insider Own 11.93% ROA -89.65% Shares Float 77.72M Beta 4.11
Inst Own 89.30% ROE -193.67% Shares Shorted/Prior 9.99M/10.29M Price 19.28
Gross Margin - Profit Margin - Avg. Volume 1,172,698 Target Price 61.75
Oper. Margin - Earnings Date - Volume 860,189 Change -1.88%
Healthcare | Biotechnology | United States
About Biohaven Ltd.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Ltd. News
12/17/24 Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
12/17/24 Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
12/16/24 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
12/06/24 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
11:51 AM Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
07:30 AM Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
11/12/24 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
10/07/24 Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy
10/03/24 Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock
10/02/24 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
10/01/24 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
09/30/24 Biohaven Announces Proposed Public Offering of Common Shares
09/30/24 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
09/26/24 Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
09/24/24 BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
09/23/24 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
09/20/24 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
08/08/24 Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?
08/08/24 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
05/29/24 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Antonijevic Irina Director Director Dec 29 Sell 41.79 11,000 459,690 2,535 12/29/23
Antonijevic Irina Director Director Dec 29 Option 0 11,000 13,535 12/29/23
CHILDS JOHN W Director Director Oct 05 Buy 22 454,545 9,999,990 2,111,663 10/10/23
Coric Vlad Chief Executive Offi.. Chief Executive Officer Oct 05 Buy 22 454,545 9,999,990 1,657,031 10/10/23
Buten Matthew Chief Financial Offi.. Chief Financial Officer Oct 05 Buy 22.00 22,727 499,994 189,380 10/06/23
Bailey Gregory Director Director Oct 04 Buy 22.568 17,817 402,094 1,525,788 10/06/23
CHILDS JOHN W Director Director Aug 30 Buy 18.4436 50,000 922,180 1,975,118 08/31/23
CHILDS JOHN W Director Director Aug 04 Buy 19.7843 100,000 1,978,430 1,925,118 08/07/23
CHILDS JOHN W Director Director Oct 25 Buy 10.5 3,709,819 38,953,100 1,825,118 03/22/23
Coric Vlad Chief Executive Offi.. Chief Executive Officer Oct 31 Buy 15.9688 25,800 411,995 1,543,394 11/01/22
Coric Vlad Chief Executive Offi.. Chief Executive Officer Oct 05 Buy 10.56 485,775 5,129,784 399,443 10/06/22
CHILDS JOHN W Director Director Oct 05 Buy 9.29 274,141 2,546,770 1,791,251 10/05/22
Heffernan Michael Thomas Director Director Oct 03 Option 3.6 23,217 83,581 24,877 10/05/22
Gentile Kimberly SVP, Clinical Operat.. SVP, Clinical Operations Oct 03 Option 2.84 115,510 328,048 133,461 10/05/22
Mehta Kishan Director Director Oct 03 Option 3.47 28,121 97,580 34,378 10/05/22
GREGORY JULIA P Director Director Oct 03 Option 3.45 28,117 97,004 28,117 10/05/22
CHILDS JOHN W Director Director Oct 03 Option 4.2 10,117 42,491 1,527,617 10/05/22
Bailey Gregory Director Director Aug 19 Buy 148.0441 38,000 5,625,676 2,583,658 08/22/22
Clark George C. VP, Chief Accounting.. VP, Chief Accounting Officer May 10 Option 53.76 2,250 120,960 8,265 05/12/22
Clark George C. VP, Chief Accounting.. VP, Chief Accounting Officer May 10 Sell 141.5 4,200 594,300 4,065 05/12/22
Doogan Declan Director Director Jun 15 Sell 68.38 41,306 2,824,504 323,912 02/11/22
Doogan Declan Director Director Jun 11 Sell 65.17 50,953 3,320,607 347,246 02/11/22
Clark George C. VP, Chief Accounting.. VP, Chief Accounting Officer Jan 19 Option 43.09 5,670 244,320 15,390 01/24/22
Clark George C. VP, Chief Accounting.. VP, Chief Accounting Officer Jan 19 Sell 117.09 9,375 1,097,719 6,015 01/24/22
Stock Elyse Chief Medical Office.. Chief Medical Officer Jan 10 Option 0.00 937 5,374 01/12/22
Mehta Kishan Director Director Jan 10 Option 0.00 1,875 10,640 01/12/22
GREGORY JULIA P Director Director Dec 20 Option 23.63 12,000 283,560 12,000 12/22/21
GREGORY JULIA P Director Director Dec 20 Sell 125 12,000 1,500,000 12/22/21
Stock Elyse Chief Medical Office.. Chief Medical Officer Dec 14 Option 15.81 28,858 456,245 29,386 12/16/21
Stock Elyse Chief Medical Office.. Chief Medical Officer Dec 14 Sell 105.54 28,858 3,045,673 7,467 12/16/21
Engelhart James Chief Financial Offi.. Chief Financial Officer Dec 10 Option 0 35,000 46,196 12/10/21
Engelhart James Chief Financial Offi.. Chief Financial Officer Dec 10 Sell 102.85 35,000 3,599,750 11,196 12/10/21
CHILDS JOHN W Director Director Nov 10 Buy 123.02 5,000 615,100 2,550,801 11/10/21